Veitch Z, Ribnikar D, Tilley D, Tang PA, et al. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. Br J Cancer 2021 Dec 20. pii: 10.1038/s41416-021-01676.
PMID: 34931041